In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 12 (4) , 324-327
- https://doi.org/10.1016/s0952-8180(00)00165-3
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight HeparinCirculation, 1999
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Emergent Cardiopulmonary Bypass in Five Patients with Heparin-induced Thrombocytopenia Type II Employing Recombinant HirudinAnesthesiology, 1998
- High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgeryBritish Journal of Haematology, 1998
- Heparin-induced Thrombocytopenia: IgG Binding to PF4-Heparin Complexes in the Fluid Phase and Cross-reactivity with Low Molecular Weight Heparin and HeparinoidThrombosis and Haemostasis, 1998
- DanaparoidDrugs, 1997
- Heparin-associated Thrombocytopenia and ThrombosisAnesthesiology, 1997
- Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass SurgeryCirculation, 1997
- Heparin-induced thrombocytopeniaJournal of Cardiothoracic and Vascular Anesthesia, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995